ACR open rheumatology · 2026
Development and Validation of the Brief Support Group Leader Self-Efficacy Scale Among Scleroderma Peer Support Group Leaders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Provencher Sabrina, Harel Daphna, Henry Richard S, Carrier Marie-Eve, Dyas Laura, Konrad Violet, Hudson Marie, Thombs Brett D, SPIN‐SSLED Support Group Advisory Team
Аннотация
OBJECTIVE: Our objective was to develop a brief Support Group Leader Self-efficacy Scale (Brief-SGLSS) that maintains the core content and measurement properties of the full 32-item SGLSS among systemic sclerosis (SSc) support group leaders.
METHODS: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient-centered Intervention Network-Scleroderma-Support group Leader Education (SPIN-SSLED) trial data and a data-driven item resampling process; (3) advisory team input to select final Brief-SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief-SGLSS and full SGLSS.
RESULTS: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6-item Brief-SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief-SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN-SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59-1.27) for the full 32-item SGLSS and 0.93 (95% CI 0.58-1.27) for the Brief-SGLSS. Convergent validity of the Brief-SGLSS and full SGLSS with other measures was similar.
CONCLUSION: The 6-item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.
METHODS: Development and validation involved four steps conducted by researchers and a Support Group Advisory Team of people with SSc: (1) item content assessment and prioritization, including a Delphi process; (2) item analysis and preliminary selection, including analysis of SGLSS measurement properties using Scleroderma Patient-centered Intervention Network-Scleroderma-Support group Leader Education (SPIN-SSLED) trial data and a data-driven item resampling process; (3) advisory team input to select final Brief-SGLSS items; and (4) comparison of convergent validity and trial change data of the Brief-SGLSS and full SGLSS.
RESULTS: Items were categorized into six content themes. Two Delphi rounds resulted in one item excluded from consideration. A 6-item Brief-SGLSS was selected at the consensus advisory panel meeting based on the resampling process and content and statistical considerations. The Pearson correlation of the Brief-SGLSS and full SGLSS was 0.96. The standardized mean difference between intervention (n = 74) and waitlist (n = 72) groups in the SPIN-SSLED trial immediately post intervention was 0.93 (95% confidence interval [CI] 0.59-1.27) for the full 32-item SGLSS and 0.93 (95% CI 0.58-1.27) for the Brief-SGLSS. Convergent validity of the Brief-SGLSS and full SGLSS with other measures was similar.
CONCLUSION: The 6-item SGLSS is shorter and more feasibly implemented than the full SGLSS and maintains similar measurement properties.